Safety, reactogenicity, and immunogenicity of a novel 24-valent pneumococcal vaccine candidate in healthy, pneumococcal vaccine-naïve Japanese adults: A phase 1 randomized dose-escalation trial

Authors

Miwa Haranaka (ORCID: https://orcid.org/0000-0001-6813-3131)
Jasdeep S. Nanra
Shite Sebastian
Ronald Smulders
Masaki Ebara
Dorota Borys (ORCID: https://orcid.org/0000-0001-9704-8462)
Gurunadh R. Chichili
Richard Malley (ORCID: https://orcid.org/0000-0002-8688-3398)
Atsuki Hashimoto
Yuki Oizumi
Takashi Nakano (ORCID: https://orcid.org/0000-0002-0135-1051)
Mioko Iwahana

Institutions

Astellas Pharma (Japan) (JP)
Kawasaki Medical School (JP)
University of Biskra (DZ)
World Wide Web Consortium (US)
GlaxoSmithKline (Belgium) (BE)
Richard Wolf (Germany) (DE)
SOUSEIKAI Global Clinical Research Center (JP)
Astellas Pharma (United States) (US)

Publication Details

Journal: Vaccine
Published: 2024-11-29
DOI: https://doi.org/10.1016/j.vaccine.2024.126545
Citations: 2
Primary Topic: Pneumonia and Respiratory Infections
Type: article
Field-Weighted Citation Impact: 0.77

Funders

GlaxoSmithKline
Astellas Pharma

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Safety, reactogenicity, and immunogenicity of a novel 24-valent pneumococcal vaccine candidate in healthy, pneumococcal vaccine-naïve Japanese adults: A phase 1 randomized dose-escalation trial

Miwa Haranaka, Jasdeep S. Nanra, Shite Sebastian, Ronald Smulders et al.

Nov 29, 2024

2 citations

Vaccine

Pneumonia and Respiratory Infections

0.77

article

Safety, reactogenicity, and immunogenicity of a novel 24-valent pneumococcal vaccine candidate in healthy, pneumococcal vaccine-naïve Japanese adults: A phase 1 randomized dose-escalation trial

Miwa Haranaka, Jasdeep S. Nanra, Shite Sebastian, Ronald Smulders, Masaki Ebara, Dorota Borys, Gurunadh R. Chichili, Richard Malley, Atsuki Hashimoto, Yuki Oizumi, Takashi Nakano, Mioko Iwahana

November 29, 2024article en

2 citations

Abstract

No abstract available for this paper.

VaccineVol. 44

Astellas Pharma (Japan) (JP), Kawasaki Medical School (JP), University of Biskra (DZ), World Wide Web Consortium (US), GlaxoSmithKline (Belgium) (BE), Richard Wolf (Germany) (DE), SOUSEIKAI Global Clinical Research Center (JP), Astellas Pharma (United States) (US)

GlaxoSmithKline, Astellas Pharma

Good health and well-being

Openalex Percentile: Top 24%

Pneumonia and Respiratory Infections

0.77

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Safety, reactogenicity, and immunogenicity of a novel 24-valent pneumococcal vaccine candidate in healthy, pneumococcal vaccine-naïve Japanese adults: A phase 1 randomized dose-escalation trial — Miwa Haranaka, Jasdeep S. Nanra, et al. · Vaccine (2024) | TGRS Research Map | TGRS